In this cohort, low expression of CD73 was associated with a higher odd for short PFS, suggesting that CD73 predicts response to Cetuximab treatment in advanced stage HNSCC (Fig. 8E). This evidence concerns the gene NT5E and head and neck squamous cell carcinoma.